PRINCETON, N.J., July 6, 2005 (PRIMEZONE) -- The Bull Market Report (http://www.bullmarket.com), a long term growth and income generating focused investment newsletter, announced today that it has provided to trial and paid subscribers updated investment analysis of pharmaceutical stocks, including coverage of Eli Lilly (NYSE:LLY), Invitrogen (Nasdaq:IVGN), Pfizer (NYSE:PFE) and Charles River Laboratories Holdings (NYSE:CRL).
In the health care sector, The Bull Market Report's Recommended List remains overweight with hold ratings on six stocks and buy ratings on three stocks.
All paid and trial subscribers to The Bull Market Report can now receive immediate access to its exclusive daily reports. As a trial or paid subscriber, you'll also gain access to our latest investment moves.
The Bull Market Report's investment outlook examines a number of issues, including:
-- A shift in focus from "blockbuster" drugs to niche drugs by
some major drugmakers and what it means.
-- The growing use of biomarkers and its impact on the industry.
-- How research & development and support services companies
will benefit from strategy changes in the pharmaceutical
industry.
-- Risks associated with developing drugs for a narrower market.
AND MORE!
Sign up now for a 14-day free trial to The Bull Market and you'll gain instant access to The Bull Market Report's in depth coverage of the financial services, health care, energy, technology, and retail, among other sectors, as well as our Recommended List of over 50 companies, by clicking here: https://www.bullmarket.com/subscribe. Subscribers also receive access to The Bull Market Report's special bonus reports, "Search Sector Outlook" and "Biotech Sector Outlook."
The Bull Market Report is perfect for investors who are serious about building a diversified investment portfolio and are committed to creating long term wealth.
About The Bull Market Report:
Launched in 1997, The Bull Market Report has a strong track record of creating wealth for its subscribers by providing sound, long term investing advice. The newsletter is ideal for investors looking for long term growth and income generating stock investments.
The Bull Market Report's Recommended List includes over 50 companies across all major industries, including Financials, Healthcare, Energy, Technology, and Retail, among others. As a testament to the durability of its value-focused and fundamentally sound recommendations in both up and down markets, The Bull Market Report is one of the oldest continuously published investment newsletters online. For more information or to sign up now for a free 14-day trial to The Bull Market Report, please visit: https://www.bullmarket.com/subscribe.
Note: This release was published by F.P. Real Ventures I, LLC (CRD #131926). Indie Research, LLC and the Bull Market editorial staff are not registered investment advisors, broker/dealers, or research analysts/organizations.